BioCentury
ARTICLE | Company News

Newco Vitaeris licenses Alder's clazakizumab

May 7, 2016 12:36 AM UTC

Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) granted newco Vitaeris Inc. (Vancouver, B.C.) exclusive, worldwide rights to anti-IL-6 mAb clazakizumab (formerly ALD518). Alder helped co-found Vitaeris to house clazakizumab, which the newco intends to develop for chronic inflammatory diseases.

Vitaeris has raised $7 million in a seed round from a syndicate including HBM Healthcare Investments, family offices including Robinson Sauder, and the newco's individual co-founders. Alder has an undisclosed equity stake in Vitaeris and is eligible for royalties. ...